Sennosides A And B

For the treatment of occasional constipation in adults and adolescents 12 years of age and older, the standard starting dose of Sennosides A and B is typically 15 mg to 17.2 mg (usually two 8.6 mg tablets) taken once daily.

• Maximum Dosage: The total daily dose should generally not exceed 34.4 mg (four 8.6 mg tablets) twice daily (68.8 mg total), although many OTC labels suggest a maximum of 34.4 mg per 24-hour period for self-medication.
• Bowel Prep Dosage: When used for colonoscopy preparation, dosages are significantly higher and are determined by a specific clinical protocol provided by the gastroenterologist.

Pediatric dosing must be approached with caution and should ideally be supervised by a pediatrician.

• Children 6 to 11 years: The typical starting dose is 8.6 mg (one tablet) once daily, usually at bedtime. The maximum dose is generally 17.2 mg per day.
• Children 2 to 5 years: The typical starting dose is 4.3 mg (half of an 8.6 mg tablet or a corresponding liquid dose) once daily. The maximum dose is 8.6 mg per day.
• Children under 2 years: Sennosides are generally not recommended for children under the age of 2 unless specifically directed by a healthcare provider, as they may cause severe dehydration or electrolyte shifts in infants.

Renal Impairment

No specific dosage adjustments are typically required for mild to moderate renal impairment due to the local action of the drug. However, patients with severe renal failure or those on dialysis should use sennosides with caution, as they are at a higher risk for electrolyte imbalances (especially hypermagnesemia if the product contains magnesium salts).

Hepatic Impairment

No dosage adjustments are generally necessary for patients with liver disease, as the drug is not significantly absorbed systemically and does not rely on hepatic metabolism for its primary effect.

Elderly Patients

Geriatric patients should start at the lowest possible dose. The elderly are more susceptible to the dehydrating effects of laxatives and may experience increased fecal incontinence or 'laxative-induced' diarrhea. Long-term use in the elderly is discouraged to prevent the development of a 'lazy bowel.'

• Timing: It is best to take Sennosides A and B at bedtime. Because the drug typically takes 6 to 12 hours to produce a bowel movement, taking it at night usually results in a bowel movement the following morning.
• Administration: Tablets should be swallowed with a full glass (8 ounces) of water or juice. This hydration is essential to help the laxative work effectively and prevent dehydration.
• Food: Sennosides can be taken with or without food. Taking them with food may help reduce the risk of stomach cramps.
• Storage: Store at room temperature (20°C to 25°C or 68°F to 77°F) in a dry place away from direct sunlight.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not double the dose to catch up, as this increases the risk of severe abdominal cramping and diarrhea.

Signs of a Sennosides A and B overdose include severe abdominal pain, nausea, vomiting, and persistent, watery diarrhea. Prolonged overdose can lead to significant dehydration and electrolyte imbalances (low potassium, low sodium). In the event of a suspected overdose, contact a Poison Control Center or seek emergency medical attention immediately. Treatment is generally supportive, focusing on rehydration and electrolyte replacement.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or use the product for more than 7 consecutive days without medical guidance.

Most patients taking Sennosides A and B will experience some degree of gastrointestinal activity, which is often a sign that the medication is working. Common side effects include:

• Abdominal Cramping: This is the most frequent complaint. It occurs because the drug stimulates the muscles of the colon to contract. The sensation is often described as a sharp, intermittent 'twinge' or pressure in the lower abdomen.
• Diarrhea or Loose Stools: If the dose is slightly higher than needed for the individual, the result may be excessively soft or watery stools.
• Urine Discoloration: Metabolites of sennosides can turn the urine a yellowish-brown, pink, or red-orange color. This is a harmless effect (pseudochromaturia) and should not be confused with blood in the urine (hematuria).

• Nausea: Some patients may feel mild stomach upset shortly after taking the medication.
• Flatulence and Bloating: As the colonic bacteria break down the sennosides, gas may be produced, leading to a feeling of fullness or increased passing of gas.
• Fecal Incontinence: Particularly in elderly patients or those with weakened sphincter muscles, the sudden urge to move the bowels can lead to accidents.

• Severe Electrolyte Imbalance: With prolonged or excessive use, patients may lose significant amounts of potassium (hypokalemia), which can lead to muscle weakness or heart rhythm issues.
• Melanosis Coli: This is a benign, reversible darkening of the lining of the colon (the mucosa). It is often discovered during a colonoscopy and is caused by the accumulation of pigment-laden macrophages. It typically resolves within 3 to 12 months after stopping the drug.
• Protein-Losing Enteropathy: Extremely rare cases of protein loss through the gut have been reported with massive laxative abuse.

> Warning: Stop taking Sennosides A And B and call your doctor immediately if you experience any of these:

• Severe Abdominal Pain: Pain that is constant, worsening, or accompanied by a rigid abdomen, which could indicate a bowel obstruction or perforation.
• Rectal Bleeding: Any sign of bright red blood in the stool or black, tarry stools after taking a laxative requires immediate investigation.
• Signs of Dehydration: Extreme thirst, very dark urine, dry skin, dizziness, or fainting.
• Hypokalemia Symptoms: Muscle cramps, heart palpitations, or extreme fatigue, which may indicate dangerously low potassium levels.
• Hypersensitivity Reactions: Though rare, some individuals may experience an allergic reaction characterized by rash, itching, swelling (especially of the face/tongue/throat), or difficulty breathing.

Chronic use of Sennosides A and B (beyond 7-10 days) can lead to several complications:

• Laxative Dependency: The colon may begin to rely on the stimulant to function, leading to a loss of natural muscular tone (sometimes called 'cathartic colon'). This makes it increasingly difficult to have a bowel movement without medication.
• Tolerance: Over time, higher doses may be required to achieve the same effect.
• Finger Clubbing: In very rare cases of extreme, long-term abuse, a reversible thickening of the fingertips (clubbing) has been observed.

No FDA black box warnings are currently issued for Sennosides A and B. However, the FDA requires a general warning on all stimulant laxatives regarding the risk of using them when abdominal pain, nausea, or vomiting are present, as these can be signs of appendicitis or bowel obstruction.

Report any unusual symptoms to your healthcare provider. For more information on side effects, you may contact the FDA at 1-800-FDA-1088.

Sennosides A and B are intended for short-term relief of occasional constipation only. They should not be used as a primary method for weight loss or for more than seven consecutive days unless under the direct supervision of a healthcare provider. Misuse of stimulant laxatives can lead to serious health complications, including permanent damage to the digestive system and life-threatening electrolyte disturbances.

There are no FDA black box warnings for Sennosides A and B. It is considered a low-risk medication when used according to the label instructions for short durations.

• Undiagnosed Abdominal Pain: Do not take Sennosides if you have severe stomach pain, nausea, or vomiting. These symptoms may indicate a serious underlying condition, such as appendicitis, bowel obstruction, or inflammatory bowel disease (IBD), which could be worsened by a stimulant laxative.
• Change in Bowel Habits: If you have noticed a sudden change in bowel habits that persists for over two weeks, consult a doctor before using a laxative.
• Allergic Reactions: While rare, individuals with a known hypersensitivity to Senna or any components of the formulation (such as certain dyes or binders) should avoid this product.
• Eating Disorders: Healthcare providers should be alert to the potential for laxative abuse in patients with anorexia nervosa or bulimia nervosa, as stimulant laxatives are frequently misused for weight control.

For occasional, short-term use, no specific laboratory monitoring is required. However, for patients who are directed by a physician to use sennosides long-term (e.g., for chronic opioid use or neurogenic bowel):

• Electrolytes: Periodic monitoring of serum potassium, sodium, and chloride is recommended.
• Renal Function: Monitoring of BUN and creatinine may be necessary in elderly or at-risk patients to ensure dehydration is not occurring.
• Clinical Assessment: Regular evaluation of the patient's need for the medication and attempts to transition to bulk-forming laxatives or lifestyle changes should be documented.

Sennosides A and B generally do not affect the ability to drive or operate machinery. However, if a patient experiences significant abdominal cramping or sudden, urgent bowel movements, their ability to focus or remain stationary may be temporarily impaired.

There is no direct chemical interaction between alcohol and Sennosides A and B. However, alcohol can contribute to dehydration, which may exacerbate the side effects of laxatives. It is recommended to limit alcohol intake while treating constipation.

If Sennosides have been used for an extended period, they should be tapered off gradually rather than stopped abruptly. Sudden discontinuation after long-term use can lead to 'rebound constipation.' Patients should be encouraged to increase dietary fiber (25-35g per day) and fluid intake (6-8 glasses of water) during the tapering process to support natural bowel function.

> Important: Discuss all your medical conditions, especially any history of bowel obstruction or inflammatory bowel disease, with your healthcare provider before starting Sennosides A And B.

There are no drugs that are strictly contraindicated for co-administration with Sennosides A and B in the same way that certain antivirals or chemotherapies interact. However, they should never be used in combination with other stimulant laxatives (like bisacodyl or castor oil) unless specifically directed by a doctor for bowel preparation, as this significantly increases the risk of severe cramping and dehydration.

• Digoxin (Lanoxin): Sennosides can cause potassium depletion (hypokalemia). Low potassium levels significantly increase the risk of digoxin toxicity, which can lead to dangerous heart arrhythmias. Patients on digoxin should be closely monitored if they require stimulant laxatives.
• Diuretics (Water Pills): Drugs such as furosemide (Lasix) or hydrochlorothiazide also deplete potassium and fluids. Using them with sennosides increases the risk of severe dehydration and electrolyte imbalances.
• Corticosteroids: Long-term use of oral steroids (like prednisone) can lower potassium levels. Combining them with sennosides further exacerbates this risk.

• Oral Medications (General): Because Sennosides A and B increase the speed at which contents move through the digestive tract (decreased transit time), they may reduce the absorption of other oral medications. It is generally recommended to take other medications at least 2 hours before or 2 hours after taking a stimulant laxative.
• Warfarin: Changes in gut flora or transit time can occasionally affect Vitamin K absorption or the stability of INR (International Normalized Ratio) levels, though this is rare with sennosides.

• Dairy Products: While there is no direct interaction with sennosides, some combination products (like those containing bisacodyl) can interact with dairy. For pure sennosides, food generally does not interfere with efficacy, but a high-fiber diet is recommended to support the drug's action.
• Hydration: Inadequate water intake can lead to the laxative being less effective and may increase the risk of cramping.

• Licorice Root (Glycyrrhiza): Natural licorice (not the candy) can lower potassium levels. Using it with sennosides increases the risk of hypokalemia.
• Other Anthraquinone Herbs: Avoid using sennosides with other herbal laxatives like Aloe vera (latex), Cascara sagrada, or Rhubarb root, as these have similar mechanisms and can lead to toxicity.
• Horsetail: This herb has diuretic properties and may increase the risk of potassium loss when used with sennosides.

• Urinary Phenols: Sennosides may interfere with the measurement of urinary phenols.
• Urine Color Tests: The discoloration of urine caused by sennoside metabolites can interfere with colorimetric lab tests (like certain dipstick tests for bilirubin or ketones), potentially leading to false-positive or uninterpretable results.

For each major interaction, the mechanism is typically pharmacodynamic (additive effects on electrolytes) or related to altered transit time. Management involves monitoring symptoms of electrolyte loss and separating the timing of doses.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those that affect heart rhythm or fluid balance.

Sennosides A and B must NEVER be used in the following circumstances:

• Bowel Obstruction or Stenosis: If the path of the stool is physically blocked, stimulating the bowel to contract can lead to severe pain, vomiting, and potentially a life-threatening bowel perforation.
• Acute Abdominal Surgery: Patients recovering from recent abdominal surgery should not use stimulant laxatives unless specifically ordered by their surgeon.
• Inflammatory Bowel Disease (IBD): Conditions such as Crohn's disease or Ulcerative Colitis involve inflammation of the intestinal lining. Sennosides can exacerbate this inflammation and may trigger a 'flare' or even toxic megacolon in severe cases.
• Appendicitis: If appendicitis is suspected (characterized by right lower quadrant pain, fever, and nausea), laxatives can cause the appendix to rupture.
• Severe Dehydration: Patients already suffering from significant fluid or electrolyte loss should not use stimulants, as they will worsen the condition.

Conditions requiring a careful risk-benefit analysis by a physician include:

• Chronic Constipation: Sennosides are not for long-term use. The underlying cause of chronic constipation (such as hypothyroidism or medication side effects) should be investigated first.
• Hemorrhoids or Anal Fissures: While passing soft stool is helpful, the increased frequency and potential for irritation from sennoside metabolites may cause discomfort in patients with acute perianal issues.
• Eating Disorders: A history of laxative abuse is a strong relative contraindication, as it poses a high risk for relapse.

There is a potential for cross-sensitivity in patients who have had allergic reactions to other anthraquinone-containing plants, such as Cascara sagrada or Frangula. If you have experienced a rash or breathing difficulties with any natural laxative, consult an allergist before using Sennosides A and B.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of 'megacolon' or intestinal 'atony,' before prescribing or recommending Sennosides A And B.

Sennosides A and B are generally considered compatible with pregnancy when used occasionally and for short durations. They are often categorized as a second-line treatment after fiber and stool softeners.

• Trimester-Specific Risks: There is no evidence of teratogenicity (birth defects) in humans. However, during the third trimester, the stimulation of the bowel could theoretically stimulate uterine contractions, although this is rarely seen with standard doses.
• Clinical Recommendation: Pregnant women should always consult their obstetrician before using any laxative, as maintaining electrolyte balance is crucial for fetal health.

Sennosides are considered 'usually compatible' with breastfeeding by the American Academy of Pediatrics.

• Passage into Milk: Active metabolites (rhein) are excreted into breast milk in very small amounts.
• Effect on Infant: Clinical studies have shown that the amount excreted is generally insufficient to cause diarrhea or increased bowel movements in the nursing infant. However, mothers should monitor their infants for any changes in stool consistency.

• Approved Age: FDA-approved for children as young as 2 years old in appropriate dosages.
• Concerns: Children are more susceptible to dehydration. Stimulant laxatives should only be used in children after lifestyle changes (increased fruit, water, and fiber) have failed.
• Conditions Not Approved For: Should not be used for 'toilet training' or as a punishment for stool withholding.

• Fall Risk: In the elderly, the urgency caused by sennosides can increase the risk of falls, especially if they need to use the bathroom during the night.
• Pharmacokinetics: While the drug itself doesn't change, the aging gut may be more sensitive to stimulants.
• Polypharmacy: Elderly patients are more likely to be on diuretics or digoxin, increasing the risk of dangerous drug-drug interactions involving potassium levels.

Patients with Chronic Kidney Disease (CKD) should use sennosides with caution. While the sennosides themselves are not nephrotoxic, the resulting shifts in potassium and sodium can be difficult for impaired kidneys to manage. Avoid formulations containing magnesium or potassium salts in this population.

No specific adjustments are required for patients with liver disease (Child-Pugh Class A, B, or C), as the drug's activity is localized to the colon and does not significantly impact or rely on hepatic function.

> Important: Special populations, particularly the elderly and pregnant women, require individualized medical assessment to ensure the safest choice of laxative.

Sennosides A and B are hydroxyanthracene glycosides. They are inactive precursors that require bacterial cleavage. In the colon, the enzyme beta-glucosidase (from bacteria like Bacteroides species) breaks the glycosidic bond, releasing the active aglycone, rheinanthrone. Rheinanthrone acts on the colonic mucosa to stimulate the myenteric plexus, increasing the rate of colonic transit. It also interacts with the epithelial cells to increase the secretion of electrolytes and water into the lumen by modulating the cyclic AMP (cAMP) pathway and inhibiting the Na+/K+-ATPase pump.

• Dose-Response: The effect is dose-dependent; higher doses lead to more liquid stools and increased frequency.
• Time to Onset: 6 to 12 hours. This delay is due to the time required for the drug to reach the colon and undergo bacterial metabolism.
• Duration: The effect typically lasts for a single bowel movement or a short series of movements over 2-4 hours once the effect begins.
• Tolerance: Prolonged use can lead to a decrease in the responsiveness of the colonic nerves to the drug.

| Parameter | Value |

|---|---|

| Bioavailability | < 5% (parent compounds) |

| Protein Binding | Not clinically significant for parent compounds |

| Half-life | Metabolites: 10-15 hours |

| Tmax | 8-12 hours (for laxative effect) |

| Metabolism | Colonic bacteria (primary); Liver (secondary for absorbed metabolites) |

| Excretion | Fecal (>90%), Renal (3-6%) |

• Molecular Formula: Sennoside A (C42H38O20); Sennoside B (C42H38O20) - they are stereoisomers.
• Molecular Weight: 862.7 g/mol.
• Solubility: Sparingly soluble in water; more soluble in alkaline solutions.
• Structure: Sennoside A is the (R,R')-isomer, and Sennoside B is the meso-form (R,S'). They consist of two linked anthrone rings with glucose molecules attached.

Sennosides A and B belong to the Anthraquinone Stimulant Laxative class. Related medications include Bisacodyl (a diphenylmethane stimulant) and Cascara Sagrada (another anthraquinone). Unlike bulk-forming laxatives (fiber) or osmotic laxatives (Miralax), sennosides actively force the bowel to move.